蛋白质的翻译后修改:结直肠癌抵抗机制的关键因素
Bo Bi1, Miaojuan Qiu2, Peng Liu1
1Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China; Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital of Sun Yat-sen University, Sun Yat-Sen University, Shenzhen, Guangdong, China.
Biochimica et biophysica acta. Gene regulatory mechanisms
|August 25, 2023
概括
翻译后修改 (PTM) 在结直肠癌 (CRC) 耐药性方面至关重要. 了解PTM提供了新的治疗策略,以克服CRC治疗中的抗性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 结肠直肠癌 (CRC) 仍然是全球癌症死亡的主要原因.
- 药物耐药性显著阻碍有效的CRC治疗结果.
- 翻译后修改 (PTMs) 极大地影响蛋白质功能和细胞过程,影响癌症的发展.
研究的目的:
- 审查了解PTMs在结直肠癌耐药性中的作用的最新进展.
- 探索PTM对关键信号通路和参与CRC抵抗的分子的功能影响.
- 确定潜在的治疗目标和克服CRC药物耐药性的策略.
主要方法:
- 关于PTM和CRC耐药性的最近研究的文献综述.
- 分析PTM对信号通路和药物开发的影响.
- 概述PTM丰富方法和未来的研究方向.
主要成果:
- 在CRC药物耐药性的发展和进展中,PTM发挥着重要作用.
- 特定的PTM会影响对CRC细胞生存和药物逃逸至关重要的信号通路.
- 目前的PTM丰富方法和向疗法显示出希望,但需要进一步开发.
结论:
- PTM是CRC耐药性的关键调节者,具有可行的治疗点.
- 进一步研究PTM和开发PTM向疗法对于改善CRC治疗至关重要.
- 需要全面的PTM分析方法来充分阐明它们在CRC耐药性中的作用.
更多相关视频
相关概念视频
Covalently Linked Protein Regulators
6.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K


